Cargando…

Crohn’s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report

BACKGROUND: Previous studied revealed that psoriasis and Inflammatory bowel disease (IBD) have highly overlapping epidemiological characteristics, genetic susceptibility loci, disease risk factors, immune mechanisms, and comorbidities. More and more biologics have been used to treat psoriasis and IB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Jingyi, Dai, Yuanyuan, Yang, Jiaolan, Liu, Changqin, Fan, Li, Feng, Lijin, Zhao, Binghui, Zeng, Meiying, Liu, Zhanju, Sun, Xiaomin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560304/ https://www.ncbi.nlm.nih.gov/pubmed/33059618 http://dx.doi.org/10.1186/s12876-020-01474-x

Ejemplares similares

Tripterygium wilfordii Polyglycoside Ameliorated TNBS-Induced Colitis in Rats via Regulating Th17/Treg Balance in Intestinal Mucosa
por: Zhang, Cui, et al.
Publicado: (2021)

Deoxycholic acid exacerbates intestinal inflammation by modulating interleukin-1β expression and tuft cell proportion in dextran sulfate sodium-induced murine colitis
por: Ju, Jingyi, et al.
Publicado: (2023)

Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis
por: Fang, Leilei, et al.
Publicado: (2022)

IL-17A exacerbates psoriasis in a STAT3 overexpressing mouse model
por: Xie, Xinran, et al.
Publicado: (2023)

The effects of IL-17/IL-17R inhibitors on atherosclerosis in psoriasis and psoriatic arthritis: A protocol for systematic review and meta analysis
por: Liu, Ningyuan, et al.
Publicado: (2021)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

Risk factors for delayed hemorrhage after colonoscopic postpolypectomy: Polyp size and operative modality
por: Liu, Changqin, et al.
Publicado: (2018)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2018)

The Role of IL-17 Cytokines in Psoriasis
por: Mosca, Megan, et al.
Publicado: (2021)

The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis
por: Chen, Liang, et al.
Publicado: (2020)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
por: Dong, Qiang, et al.
Publicado: (2022)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

The contribution of IL-17 to the development of autoimmunity in psoriasis
por: Furue, Masutaka, et al.
Publicado: (2019)

Levels of TB-IGRA may help to differentiate between intestinal tuberculosis and Crohn’s disease in patients with positive results
por: Zhao, Yujie, et al.
Publicado: (2020)

Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors
por: Koike, Yuta, et al.
Publicado: (2020)

Keratin 17 covalently binds to alpha-enolase and exacerbates proliferation of keratinocytes in psoriasis
por: Luo, Yixin, et al.
Publicado: (2023)

High-fat-diet-associated intestinal microbiota exacerbates psoriasis-like inflammation by enhancing systemic γδ T cell IL-17 production
por: Sonomoto, Koshiro, et al.
Publicado: (2023)

miR-31-5p-DMD axis as a novel biomarker for predicting the development and prognosis of sporadic early-onset colorectal cancer
por: Liu, Changqin, et al.
Publicado: (2022)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Immune regulation mechanism of vitamin D level and IL-17/IL-17R pathway in Crohn's disease
por: Xia, Yanli, et al.
Publicado: (2019)

The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
por: Kokolakis, Georgios, et al.
Publicado: (2022)

Differentiation of IL-26(+) T(H)17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis
por: Fries, Anissa, et al.
Publicado: (2023)

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
por: Blauvelt, Andrew, et al.
Publicado: (2018)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
por: von Stebut, Esther, et al.
Publicado: (2020)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
por: Glatt, Sophie, et al.
Publicado: (2017)

The IL-17 receptor IL-17RE mediates polyIC-induced exacerbation of experimental allergic asthma
por: Vella, Giovanna, et al.
Publicado: (2020)

Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond
por: Pușcaș, Alexandra Dana, et al.
Publicado: (2023)

Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis
por: Costache, Daniel Octavian, et al.
Publicado: (2022)

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
por: Tsiogka, Aikaterini, et al.
Publicado: (2023)

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
por: Kutwin, Magdalena, et al.
Publicado: (2021)

An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients
por: Orzan, Olguța Anca, et al.
Publicado: (2023)

Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis
por: Singh, Tej Pratap, et al.
Publicado: (2013)

Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
por: Zou, Yulin, et al.
Publicado: (2021)

Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study
por: Borg, Emma, et al.
Publicado: (2021)

The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis
por: Girolomoni, G., et al.
Publicado: (2017)

An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients
por: Bassolas-Molina, Helena, et al.
Publicado: (2018)

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
por: Gaspari, Anthony A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u94o5khv3rhtg2j9411481va49